According to filings with the U.S. Securities and Exchange Commission, Neumora Therapeutics is raising $100,000,000.00 in new funding. About Neumora Therapeutics: Redefining Neuroscience Drug Development to Pioneer a New Era of Medicines for Brain Diseases. We are a clinical biopharmaceutical company developing therapies that target brain diseases as well as major depression and other neuropsychiatric brain disorders. (Incorporated in Delaware). We are facing a global brain disease crisis, but we are lacking targeted, effective medicines. Patients deserve better. Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches.

To learn more about Neumora Therapeutics, visit http://www.neumoratx.com/

Contact:
Henry Gosebruch, Chief Executive Officer
857-760-0900
https://www.linkedin.com/in/henry-gosebruch-3834608/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.